close
Generic drugs

Generic Drugs Market in United States, By Type, By Application, By Drug Delivery Method, By Form, By Source, By Distribution Channel, By Region, Competition, Forecast And Opportunity, 2026

Generic Drugs Market in United States, By Type (Small Molecule Generics Vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Infectious Diseases, Others), By Mode Of Drug Administration (Oral, Topical, parenteral, other), by form (tablet, capsule, injection, other), by source (in-house or contract manufacturing organizations), by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, others), by region, competition, forecast and opportunities, 2026

New York, December 23, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Generic Drugs Market in United States, By Type, By Application, By Drug Administration, By Form, By Source, by distribution Channel, by region, competition, forecast and opportunities, 2026 “- https://www.reportlinker.com/p06192577/?utm_source=GNW

The US generic drug market was valued at USD 70.78 billion in 2020 and is expected to grow at a CAGR of 9.43% during the forecast period and may reach a market value of USD 126.74 billion by 2026. Factors such as the profitable nature of generic drugs and increasing demand from developing economies are primarily responsible for this estimate of the futuristic growth of the US generic drug market over the next five years. Generic drugs do not require extensive research and development like prescription drugs and patented drugs. Market players and research institutes invest heavily in pharmaceutical patents. In addition, FDA approvals for generic drugs are not required because the generic drugs contain the same composition as the previously patented drug and thus support the growth of the US generic drug market over the next five years. The healthcare industry in the United States, in terms of generic drugs, has gone from an 80% growth in 2020 to a previous growth of 20% in 2015.
Increasing exports of generic drugs to developing economies like Kenya, India etc. also confirms the growth of the US generic drug market in the next five years.
The generic drugs market in the United States is segmented on the basis of drug type, mode of administration, form, source of manufacture, application, company, and regional distribution. Based on type, the market can be divided into generics and small molecule biosimilars.

Small Molecule Generics are expected to achieve the largest market revenue shares and dominate the market segment over the next five years due to their simpler and easier manufacturing processes. Manufacturers of generic drugs when producing generics with small molecules are required to prove that the end product contains chemical compounds identical to those of the patented drug.

With similar pharmacokinetic functions and properties, the generic small molecule is accepted. In addition, the demand for cost-effective generic drugs is expected to further support the growth of the US generic drug market over the next five years.
Based on the applications, the market may be fragmented into cardiovascular disease, diabetes, neurology, oncology, infectious disease, and others. Cardiovascular disease is expected to dominate the market segment while recording the largest market revenue shares over the next five years on account of growing cardiovascular disease cases in the United States.

Additionally, the increased demand for the treatment and extended drug regimens is driving the growth of the cardiovascular disease sub-segment while supporting the growth of the generic drug market in the United States over the next five years. Increased pharmaceutical research and development for the oncologic disease is expected to drive the growth of the oncology sub-segment and drive the growth of the US generic drug market over the next five years.
Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sandoz US, Endo Pharmaceuticals Inc., Aurobindo Pharma USA, Inc., Abbott Laboratories Inc., Eli Lilly and Company, Sun Pharma Inc., Lupine Pharmaceuticals, Inc. and Zydus Pharmaceutical USA Inc. is among the major market players in United States leading the growth of the generic drug market.

Years considered for this report:

Historical years: 2016-2019
Baseline year: 2020
Estimated year: 2021
Forecast period: 2022-2026

Goal of the study:

• To analyze the historical growth in the market size of the generic drugs market in the United States from 2016 to 2020.
• Estimate and forecast the US generic drugs market size from 2021 to 2026 and the growth rate to 2026.
• To categorize and forecast the United States generic drug market on the basis of drug type, application, drug administration route, form, source, distribution channel, competitive landscape, and regional distribution.
• Identify the dominant region or segment in the generic drug market in the United States.
• Identify the drivers and challenges of the US generic drug market.
• Examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the US generic drug market.
• Identify and analyze the profile of the main players operating in the US generic drug market.
• Identify the main sustainable strategies adopted by the players in the generic drugs market in the United States.
The analyst performed both primary and secondary research exhaustive for this study. Initially, the analyst found a list of manufacturers around the world.

Subsequently, the analyst conducted primary research surveys of the identified companies. During the interviews, respondents were also asked about their competitors.

Using this technique, the analyst could include manufacturers who could not be identified due to the limitations of secondary research. The analyst looked at manufacturers, distribution channels and the presence of all major players across the globe.
The analyst calculated the size of the generic drugs market in the United States using a bottom-up approach, in which data from various end-user segments was recorded and forecast for years to come. The analyst obtained these values ​​from industry experts and company representatives and validated them externally by analyzing historical data for these types of products and applications to arrive at an appropriate overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations, and financial reports were also investigated by the analyst.

Key target audience:

• Manufacturers, suppliers, distributors and other stakeholders of generic drugs
• Government bodies such as regulatory authorities and policy makers
• Organizations, forums and alliances related to generic drugs
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important to industry players such as manufacturers, suppliers, partners, end users, etc., in addition to enabling them to develop investment strategies and capitalize on market opportunities.

Scope of the report:

In this report, the United States Generic Drugs Market has been segmented into the following categories in addition to industry trends which have also been detailed below:
• Generic Drugs Market in United States, by Type:
o Generic Small Molecule
o Biosimilars
• United States Generic Drugs Market, By Application:
o Cardiovascular diseases
o Diabetes
o Neurology
o Oncology
o Infectious diseases
o Others
• Generic drug market in the United States, by drug administration method:
o Oral
o Parenteral
o Topical
o Others
• Generic Drugs Market in United States, by Form:
Tablet
o Capsule
o Injection
o Others
• Generic drugs in the United States, by source:
o In-house manufacturing
o Contract manufacturing organizations
• Generic drug market in the United States, by distribution channel:
o Retail pharmacies
o Online pharmacies
o Hospital pharmacies
o Others
• Generic drug market in United States, by region:
o South
o Midwest
o West
o North East

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global generic drugs market.

Customizations available:

With the market data provided, we offer customizations based on the specific needs of a business. The following customization options are available for the report:

Company Info

• Detailed analysis and profiling of additional market players (up to five).
Read the full report: https://www.reportlinker.com/p06192577/?utm_source=GNW

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Joan J. Dean

The author Joan J. Dean